GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Innoviva Inc (NAS:INVA) » Definitions » Shiller PE Ratio

Innoviva (Innoviva) Shiller PE Ratio : 9.30 (As of May. 16, 2024)


View and export this data going back to 2004. Start your Free Trial

What is Innoviva Shiller PE Ratio?

As of today (2024-05-16), Innoviva's current share price is $15.905. Innoviva's E10 for the quarter that ended in Mar. 2024 was $1.71. Innoviva's Shiller PE Ratio for today is 9.30.

The historical rank and industry rank for Innoviva's Shiller PE Ratio or its related term are showing as below:

INVA' s Shiller PE Ratio Range Over the Past 10 Years
Min: 8.5   Med: 20.59   Max: 144.6
Current: 9.3

During the past years, Innoviva's highest Shiller PE Ratio was 144.60. The lowest was 8.50. And the median was 20.59.

INVA's Shiller PE Ratio is ranked better than
92% of 150 companies
in the Biotechnology industry
Industry Median: 35.34 vs INVA: 9.30

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Innoviva's adjusted earnings per share data for the three months ended in Mar. 2024 was $0.460. Add all the adjusted EPS for the past 10 years together and divide 10 will get our E10, which is $1.71 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Innoviva Shiller PE Ratio Historical Data

The historical data trend for Innoviva's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Innoviva Shiller PE Ratio Chart

Innoviva Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 36.58 20.96 11.99 10.15

Innoviva Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.25 9.94 8.98 10.15 8.93

Competitive Comparison of Innoviva's Shiller PE Ratio

For the Biotechnology subindustry, Innoviva's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Innoviva's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Innoviva's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Innoviva's Shiller PE Ratio falls into.



Innoviva Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Innoviva's Shiller PE Ratio for today is calculated as

Shiller PE Ratio=Share Price/ E10
=15.905/1.71
=9.30

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Innoviva's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, Innoviva's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.46/131.7762*131.7762
=0.460

Current CPI (Mar. 2024) = 131.7762.

Innoviva Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 -0.570 100.560 -0.747
201409 -0.190 100.428 -0.249
201412 -0.130 99.070 -0.173
201503 -0.090 99.621 -0.119
201506 -0.070 100.684 -0.092
201509 -0.040 100.392 -0.053
201512 0.040 99.792 0.053
201603 0.040 100.470 0.052
201606 0.130 101.688 0.168
201609 0.130 101.861 0.168
201612 0.220 101.863 0.285
201703 0.150 102.862 0.192
201706 0.300 103.349 0.383
201709 0.210 104.136 0.266
201712 0.500 104.011 0.633
201803 0.270 105.290 0.338
201806 0.490 106.317 0.607
201809 0.430 106.507 0.532
201812 2.340 105.998 2.909
201903 0.310 107.251 0.381
201906 0.340 108.070 0.415
201909 0.360 108.329 0.438
201912 0.420 108.420 0.510
202003 0.590 108.902 0.714
202006 0.690 108.767 0.836
202009 0.260 109.815 0.312
202012 0.480 109.897 0.576
202103 0.840 111.754 0.990
202106 0.900 114.631 1.035
202109 0.900 115.734 1.025
202112 0.140 117.630 0.157
202203 0.200 121.301 0.217
202206 0.010 125.017 0.011
202209 2.800 125.227 2.946
202212 -0.980 125.222 -1.031
202303 0.420 127.348 0.435
202306 0.020 128.729 0.020
202309 0.980 129.860 0.994
202312 0.760 129.419 0.774
202403 0.460 131.776 0.460

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Innoviva  (NAS:INVA) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Innoviva Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Innoviva's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Innoviva (Innoviva) Business Description

Traded in Other Exchanges
Address
1350 Old Bayshore Highway, Suite 400, Burlingame, CA, USA, 94010
Innoviva Inc develops biopharmaceutical drugs in the antibiotic, respiratory, and digestive realms. Theravance's respiratory compounds are in late-stage trials for asthma and chronic obstructive pulmonary disease. Its product offering includes Relvar/Breo/Ellipta, Anoro, Ellipta, Trelegy, Ellipta and others. The firm collaborates with and receives funding from GlaxoSmithKline.
Executives
Marianne Zhen officer: Chief Accounting Officer C/O INNOVIVA, INC., 2000 SIERRA POINT PARKWAY, SUITE 500, BRISBANE CA 94005
Stephen Basso officer: Chief Financial Officer C/O INOZYME PHARMA, INC., 321 SUMMER STREET, SUITE 400, BOSTON MA 02210
Margaret Koziel officer: Chief Medical Officer C/O AXCELLA HEALTH INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Alexander J Denner 10 percent owner C/O SARISSA CAPITAL MANAGEMENT LP, 660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830
Deborah Birx director 3300 LOWELL STREET NW, WASHINGTON DC 20008
Sarissa Capital Management Lp 10 percent owner 660 STEAMBOAT ROAD, GREENWICH CT 06830
Pavel Raifeld officer: Chief Executive Officer 1350 OLD BAYSHORE HIGHWAY, SUITE 400, BURLINGAME CA 94010
Sapna Srivastava director C/O MYOS CORPORATION, 45 HORSEHILL ROAD, SUITE 106, CEDAR KNOLLS NJ 07927
Larry G. Edwards officer: CEO of La Jolla Pharmaceutical C/O TETRAPHASE PHARMACEUTICALS, INC., 480 ARSENAL STREET, SUITE 110, WATERTOWN MA 02472
Plc Glaxosmithkline 10 percent owner 980 GREAT WEST ROAD, BRENTFORD MIDDLESEX X0 TW8 9GS
Mark Dipaolo director 660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830
Kostas D Odysseas director 660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830
Sarah J. Schlesinger director C/O ARIAD PHARMACEUTICALS, 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Jules Haimovitz director 601 108TH AVENUE NE, SUITE 1200, BELLEVUE WA 98004
George Bickerstaff director C/O VION PHARMACEUTICALS, INC., 4 SCIENCE PARK, NEW HAVEN CT 06511